Merck & Co, Lundbeck stop joint development of gaboxadol for insomnia |
|
|
|
Published
:
Wed, 28 Mar 2007 14:14
|
LONDON (AFX) - Merck & Co and H Lundbeck AS said they have discontinued their joint development program for gaboxadol, an investigational new medicine for the treatment of insomnia currently in Phase III development.In a joint statement, the companies said that data from recently completed clinical studies suggest that the overall clinical profile for gaboxadol in insomnia does not support further development.As a result, Merck and Lundbeck will not file a new drug application for gaboxadol for the treatment of insomnia with the US Food and Drug Administration or any other regulatory agencies worldwide, and are terminating ongoing clinical studies.newsdesk@afxnews.comcmlCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Danish shares lower midmorning; Lundbeck, Novo Nordisk lower 